Ursodeoxycholic Acid Market Size and Trends

Ursodeoxycholic Acid Market, By Dosage Form (Solid Dosage Form and Liquid Dosage Form), By Mode of Extraction (Synthetic and Biological), By Application (Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Feb 2025

Code : CMI2199

Pages :160

Formats :

Excel and PDF

Industry : Pharmaceutical

Ursodeoxycholic Acid Market Size and Trends

Global ursodeoxycholic acid market is estimated to be valued at USD 651.5 Mn in 2025 and is expected to reach USD 1,303.1 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 10.4% from 2025 to 2032.

Ursodeoxycholic Acid Market Key Factors

To learn more about this report, Request sample copy

Market Driver - Increasing prevalence of gallstones

Rising prevalence of gallstones across the globe can drive the market growth. Gallstones are solid deposits of cholesterol or bilirubin that form in the gallbladder. These are very common among adults aged 40 years and above. According to recent studies, around 10-15% of the adult population in America and Europe have gallstones. The major risk factors that lead to rise in gallstones include obesity, diabetes, rapid weight loss, and high cholesterol levels.

With changing lifestyles and dietary patterns, there have been increase in consumption of high fat/calorie diets. These diets interfere with normal gallbladder functioning and increase the likelihood of stones forming over time. As modernization spreads across developing regions, the westernization of diets also brings along non-communicable diseases like obesity.

The treatment for symptomatic gallstones is generally a surgical procedure called cholecystectomy, which involves removal of the gallbladder. Ursodeoxycholic acid (UDCA) plays an important adjuvant or alternative role in the management of gallstones. It helps dissolve small cholesterol gallstones and reduces symptoms in some patients, thus, delaying or avoiding surgery. It also finds application in dissolving residual stones post-surgery. With increasing patient pool suffering from gallstones, there will be huge demand for UDCA and related formulations.

For Instance, In April 2022, approximately 20 million Americans are estimated to have gallstone disease, according to an article from NCBI. Annually, nearly 300,000 cholecystectomy procedures are performed among these individuals. About 20% of gallstones are symptomatic, while approximately 10% are asymptomatic.